Carrimycin for HLH patients with resistant infections
Part of Blood & lymphatic clinical trials.
This trial tests an oral antibiotic called carrimycin in people with HLH who have an infection that isn't responding to standard strong antibiotics. It aims to see if carrimycin can safely and effectively treat these hard-to-treat infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with HLH (hemophagocytic lymphohistiocytosis), a condition where your immune system becomes overactive.
- You currently have an active infection that hasn't improved after 72 hours of treatment with a strong antibiotic called carbapenems.
- You are over 18 years old.
- You are able to take pills by mouth and don't have severe liver disease or other serious health issues that would make the trial unsafe.
- You are not pregnant, breastfeeding, or allergic to carrimycin (the study drug).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted drug (ruxolitinib) with a less intense version of standard chemo for adults with Hemophagocytic Lymphohistiocytosis (HLH). It aims to control the overactive immune response while reducing side effects.
This trial looks at how people with lymphoma-related hemophagocytic lymphohistiocytosis (HLH) respond to treatment. It aims to better describe expected outcomes and who benefits most, which may help guide future care.
This trial tests a modified combination of drugs (liposomal doxorubicin, etoposide, and ruxolitinib, with or without a PD-1 inhibitor) for people with HLH. The goal is to see if it helps control the overactive immune response better than standard care.
This trial tests a new combination of medicines (the GO regimen) for people with hemophagocytic lymphohistiocytosis (HLH) that is either newly diagnosed, has come back, or hasn't responded to other treatments. It aims to see if this approach can help when a stem cell transplant isn't an option right now.
This trial tests a new drug called plonmarlimab for people with a rheumatic (joint or immune) disease who also have a dangerous overreaction of their immune system called HLH (or MAS). The goal is to see if the drug can help when high-dose steroids have not worked or are not an option.
This trial tests a new combination of three drugs (BRII-5395, sintilimab, and bevacizumab) for advanced hepatocellular carcinoma (liver cancer) in patients with hepatitis B who have not responded well to previous treatments. The goal is to evaluate whether this combination is safe and effective.
Hear when a new Carbapenem Resistant Bacterial Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.